IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin

Diabetes Care

Volumn 25, Issue 7, 2002, Pages 1192-1197

  Christie, Michael R ^a   Molvig, Jens ^b   Hawkes, Charlotte J ^b   Carstensen, Bendix ^b   Mandrup Poulsen, Thomas ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CYCLOSPORIN; GLUCAGON; IA ANTIBODY; INSULIN; ANTIDIABETIC AGENT; AUTOANTIBODY; GLYCOSYLATED HEMOGLOBIN; ICA512 AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ARTICLE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; RADIOASSAY; REMISSION; ADULT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; IMMUNOLOGY; MALE; MULTICENTER STUDY; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AUTOANTIBODIES; C-PEPTIDE; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; MALE; PLACEBOS; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 0036633893     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.7.1192     Document Type: Article

References (20)

1. Christie MR: Islet proteins implicated in pathogenesis of type 1 diabetes. Adv Mol Cell Biol 29:75-100, 1999
2. The Canadian-European Randomised Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574-1582, 1988
3. Bougneres PF, Carel JC, Castano L, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chausain JL, Bach JF: Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 318:663-670, 1988
4. Petersen JS, Dyrberg T, Karlsen AE, Molvig J, Michelsen B, Nerup J, Mandrup-Poulsen T, Canadian European Randomized Control Trial Group: Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of β-cell function and remission in recent onset IDDM after cyclosporin treatment. Diabetes 43:1291-1296, 1994
5. Mandrup-Poulsen T, Nerup J, Stiller D, Marner B, Bille G, Heinrichs D, Martell R, Dupre J, Keown PA, Jenner MR, Rodger MW, Wolfe B: Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 2:599-602, 1985
6. Mandrup-Poulsen T, Molvig J, Andersen HU, Helqvist S, Spinas GA, Munck M, Canadian European Randomized Control Trial Group: Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. Diabetes 39:204-210, 1990
7. Christie MR, Roll U, Payton MA, Hatfield ECI, Ziegler AG: Validity of screening for individuals at risk for type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 20:965-970, 1997
8. Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Gale EAM, Bonifacio E, and Bottazzo GF: Antibodies to islet 37k-antigen, but not to glutamate decarboxylase, discriminate rapid progression to insulin-dependent diabetes mellitus in endocrine autoimmunity. Diabetes 43:1254-1259, 1994
9. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
10. Verge CF, Stenger D, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS, participating laboratories: Combined use of autoantibodies (IA-2 autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 47:1857-1866, 1998
11. McCullagh P, Nelser JA: Generalized Linear Models. London, Chapman & Hall, 1984
12. Selmer R: A comparison of Poisson regression models fitted to multiway summary tables and Cox's survival model using data from a blood pressure screening in the city of Bergen Norway. Stat Med 9:1157-1166, 1990
13. Littell RC, Milliken GA, Stroup WW, Wolfinger RD: SAS system for mixed models. Cary, NC, SAS Institute, 1996
14. Myers MA, Rabin DU, Rowley MJ: Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44:1290-1295, 1995
15. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E: Identification of protein tyrosine phosphatase-like IA-2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40k autoantigen and a target of islet cell antibodies. J Immunol 155:5419-5426, 1995
16. Sabbah E, Savola K, Veijola R, Vahasalo P, Karjalainen J, Akerblom HK, Knip M, the Childhood Diabetes in Finland Study Group: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab 84:1534-1539, 1999
17. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R, Winnock F, ver Elst K, Weets I, Kaufman L, Pipeleers DG, Gorus FK, the Belian Diabetes Registry: Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Diabetes Care 23:1072-1078, 2000
18. Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme J, Eriksson J, Littorin B, Nystrom L, Sundkvist G: Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflect different courses of beta cell damage. Autoimmunity 33:115-120, 2001
19. Genovese S, Bonfanti R, Bazzigaluppi E, Lampasona V, Benazzi E, Bosi E, Chiumello G, Bonifacio E: Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39:1223-1226, 1996
20. Sabbah E, Savola K, Kulmala P, Reijonen H, Veijola R, Vahasalo P, Karjalainen J, Ilonen J, Akerblom HK, Knip M, the Childhood Diabetes in Finland Study Group: Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). Clin Exp Immunol 116:78-83, 1999